Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Add To Watchlist

Recent & Breaking News (NDAQ:GILD)

Kite Completes Acquisition of Tmunity

Business Wire February 22, 2023

Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients

Business Wire February 21, 2023

Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies

Business Wire February 21, 2023

Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer

Business Wire February 17, 2023

Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023

Business Wire February 14, 2023

Kite's Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Business Wire February 9, 2023

U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer

Business Wire February 3, 2023

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend

Business Wire February 2, 2023

Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results

Business Wire February 2, 2023

Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

Business Wire February 1, 2023

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

Business Wire January 30, 2023

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire January 27, 2023

Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023

Business Wire January 19, 2023

Gilead Sciences Again Named to Dow Jones Sustainability World Index

Accesswire January 5, 2023

Gilead Sciences: Connecting Breast Cancer Education to Community: Equal Hope

Accesswire January 4, 2023

Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies

Business Wire January 3, 2023

European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer

Business Wire January 3, 2023

Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics

GlobeNewswire December 27, 2022

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

Business Wire December 27, 2022

Gilead Sciences to Present at Upcoming Investor Conference

Business Wire December 23, 2022